Several small-molecule inhibitors targeting the PI3K/AKT/mTOR pathway are being developed as cancer therapeutics, including pan-PI3K inhibitors, isoform-specific PI3K inhibitors, dual PI3K/mTOR inhibitors, mTORC1 inhibitors, dual mTORC1/2 inhibitors, and AKT inhibitors17. Here, PIK3CA is linked to cancer.